Get the Stockscreener App
69.17
1.43%
-1.00
After Hours:
69.40
0.23
+0.33%
Boston Scientific Corp stock is traded at $69.17, with a volume of 16.01M.
It is down -1.43% in the last 24 hours and down -9.99% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$70.17
Open:
$70.03
24h Volume:
16.01M
Relative Volume:
1.13
Market Cap:
$102.80B
Revenue:
$20.08B
Net Income/Loss:
$2.89B
P/E Ratio:
35.67
EPS:
1.9391
Net Cash Flow:
$3.66B
1W Performance:
-0.45%
1M Performance:
-9.99%
6M Performance:
-29.55%
1Y Performance:
-31.38%
1-Day Range:
$68.85
$70.13
1-Week Range:
$68.03
$71.20
52-Week Range:
$67.56
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
69.17 | 102.80B | 20.08B | 2.89B | 3.66B | 1.9391 |
ABT
Abbott Laboratories
|
103.99 | 180.70B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.44 | 125.40B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
79.34 | 45.74B | 6.07B | 1.06B | 1.34B | 1.8063 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific at American College of Cardiology: Clinical Trials Drive Growth - Investing.com
Boston Scientific Unveils “Practice-Transforming” Trial Data for PE and AF at ACC Conference Call - Yahoo Finance
One-time heart implant cut bleeding vs. blood thinners in 3,000-patient trial - Stock Titan
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism – Company AnnouncementFT.com - Financial Times
25,000 Shares in Boston Scientific Corporation $BSX Bought by Waycross Partners LLC - MarketBeat
Boston Scientific Corp (NYSE:BSX) Presents a Compelling Mix of Strong Fundamentals and Technical Breakout Potential - ChartMill
Avity Investment Management Inc. Has $20.76 Million Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Boston Scientific (NYSE:BSX) Cut to "Hold" at Wall Street Zen - MarketBeat
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
BSX Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Bernstein reiterates Boston Scientific stock rating ahead of trial data - Investing.com
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit - Barchart.com
Boston Scientific Corp Stock (BSX) Moved Up by 3.66% on Mar 26: Key Drivers Unveiled - TradingKey
Boston Scientific Corp. Stock: Navigating Electrophysiology Challenges Amid Strong Cardiovascular Gr - AD HOC NEWS
Portnoy Law Firm Announces Class Action on Behalf of Boston Scientific Corporation Investors - GlobeNewswire Inc.
BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT - GlobeNewswire
Why The Narrative Around Boston Scientific (BSX) Is Shifting As Analysts Reset Expectations - Yahoo Finance
SG Americas Securities LLC Sells 19,225 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corp. stock faces pressure amid medtech sector slowdown and pipeline delays - AD HOC NEWS
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
BSX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Boston Scientific (BSX): Company Profile, Stock Price, News, Rankings - Fortune
Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade) - Seeking Alpha
Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX - ChartMill
Is Boston Scientific Corporation (BSX) A Good Stock To Buy Now? - Insider Monkey
Boston Scientific Corp. stock shows resilient fundamentals amid volatile medtech market pressures - AD HOC NEWS
Why Boston Scientific's Big Dip Could Be a Bigger Opportunity - The Globe and Mail
BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - GlobeNewswire Inc.
Deadline Alert: Boston Scientific Corporation (BSX) - GlobeNewswire
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $90 to $120 - 富途牛牛
BSX Shareholder Alert: Boston Scientific Corporation Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - Barchart
Evercore ISI reiterates Boston Scientific stock rating on growth outlook - Investing.com UK
Evercore ISI reiterates Boston Scientific stock rating on growth outlook By Investing.com - Investing.com India
Stifel reiterates Boston Scientific stock rating ahead of trial data - Investing.com
Boston Scientific (BSX) Joins Evercore's Tactical Outperform Lis - GuruFocus
Boston Scientific Corporation $BSX Shares Sold by Park Avenue Securities LLC - MarketBeat
BSX Stock Quote Price and Forecast - CNN
Avanza Fonder AB Acquires 21,210 Shares of Boston Scientific Corporation $BSX - MarketBeat
Robbins LLP Urges BSX Stockholders Who Lost Money Investing in Boston Scientific Corporation to Contact the Firm for Information About Leading the Class Action - Barchart.com
Westview Management dba Westview Investment Advisors Buys New Stake in Boston Scientific Corporation $BSX - MarketBeat
ROSEN, A RANKED AND LEADING FIRM, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
BSX INVESTOR ALERT: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law - The Norfolk Daily News
Boston Scientific (NYSE:BSX) Falls as Recall Draws S&P 500 Focus - Kalkine Media
Tounjian Advisory Partners LLC Makes New Investment in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific’s EMEA Urology Push May Reframe Valuation Story - simplywall.st
Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback? - Yahoo Finance
BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Boston Scientific Corp Stock (BSX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 16 '26 |
Option Exercise |
0.00 |
905 |
0 |
6,433 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 14 '26 |
Option Exercise |
0.00 |
1,190 |
0 |
5,977 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 13 '26 |
Option Exercise |
0.00 |
500 |
0 |
4,986 |
| Woodworth Emily | SVP, Global Controller and CAO |
Feb 16 '26 |
Option Exercise |
0.00 |
637 |
0 |
2,676 |
| Woodworth Emily | SVP, Global Controller and CAO |
Feb 14 '26 |
Option Exercise |
0.00 |
661 |
0 |
2,335 |
| Woodworth Emily | SVP, Global Controller and CAO |
Feb 13 '26 |
Option Exercise |
0.00 |
1,413 |
0 |
2,364 |
| Monson Jonathan | EVP and CFO |
Feb 16 '26 |
Option Exercise |
0.00 |
990 |
0 |
38,426 |
| Monson Jonathan | EVP and CFO |
Feb 14 '26 |
Option Exercise |
0.00 |
1,058 |
0 |
37,906 |
| Monson Jonathan | EVP and CFO |
Feb 13 '26 |
Option Exercise |
0.00 |
1,766 |
0 |
37,636 |
| O'Sullivan Miriam | SVP, Chief HR Officer |
Feb 16 '26 |
Option Exercise |
0.00 |
990 |
0 |
17,593 |
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):